Wall Street Zen Upgrades SciSparc (NASDAQ:SPRC) to Hold

SciSparc (NASDAQ:SPRC) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of SciSparc in a research report on Tuesday, May 26th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

SciSparc Stock Performance

SciSparc stock opened at $5.00 on Friday. SciSparc has a 1 year low of $2.98 and a 1 year high of $80.10. The firm’s 50 day moving average price is $6.51 and its two-hundred day moving average price is $6.55.

SciSparc (NASDAQ:SPRC) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($31.60) EPS for the quarter. The firm had revenue of $0.20 million during the quarter.

SciSparc Company Profile

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.